From development to delivery: moxidectin and dovramilast to fight neglected tropical diseases and improve access to medicines in the Indo-Pacific
Australia is supporting Medicines Development for Global Health (MDGH) to advance the development and delivery of two medicines, moxidectin and dovramilast, for the treatment of some of the world’s most challenging, disfiguring and stigmatising infectious diseases. Scabies, lymphatic filariasis and leprosy type 2 reaction negatively impact the lives of hundreds of millions of people globally and have some of the highest reported prevalence rates in the Indo-Pacific.